Posted inGenetics
Spatial Transcriptomics Tools May Link Tumor Organization to Treatment Response
Credit: Marcin Klapczynski/Getty Images Spatial transcriptomics has given cancer researchers a powerful way to see not only which genes are…
Posted inGenetics
Single-Use Comes of Age—What Comes Next?
Credit: Extreme Photographer/Getty Images For much of the past two decades, the biopharmaceutical industry has assessed single-use technologies in terms…
Posted inGenetics
‘One-Two Punch’ Targets Resistance Mechanism in Aggressive Triple-Negative Breast Cancer
Credit: NEMES LASZLO/Science Photo Library/ Getty Images Triple-negative breast cancer (TNBC) may initially respond well to chemotherapy but will often…
Posted inBiotechnology
Novartis, Bristol Myers halt autoimmune CAR-T trials due to adverse events
Novartis and Bristol Myers Squibb have halted several CAR-T trials in autoimmune diseases due to immune-related adverse events, Fierce has…
Posted inGenetics
Key Immune Cells Identified That Could Strengthen Flu Vaccines
Credit: urfinguss / iStock / Getty Images Plus Influenza continues to be a major source of illness in the United…
Posted inGenetics
Darpa Awards UC San Diego Up to $11.3 Million for ‘Smarter’ Red Blood Cells
Credit: Koto Feja/Getty Images Scientists at the University of California San Diego School of Medicine have been awarded a contract…
Posted inBiotechnology
ESC: Alnylam’s next-gen silencer sees silver linings after fallout of AZ, Ionis trial in ATTR-CM
As AstraZeneca appears to close the book on a combo approach following the phase 3 failure of its Ionis-partnered Wainua,…
Posted inGenetics
Synthetically Engineered Marine Bacteria Could Play Key Role in Decarbonizing the Atmosphere at Industrial Scales
Credit: Stein Photo/Getty Images Rock weathering is a major regulator of Earth’s atmospheric CO2 levels and climate, according to scientists. Throughout…
Posted inBiotechnology
Electra aims to light up Nasdaq with IPO for phase 2/3 I&I push
The 2026 IPO streak continues as Electra Therapeutics has filed to go public to support its immunology and cancer pipeline.
Posted inBiotechnology
ESC26: AstraZeneca’s heart failure drug shows promise in ph. 2 trial
AstraZeneca’s oral relaxin agonist delivered encouraging phase 2b results in chronic heart failure, improving measures of cardiac function across two…